The New England Journal of Medicine | Research & Review Articles …
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Management of Insomnia | New England Journal of Medicine
Jul 17, 2024 · Insomnia is common and frequently occurs with other disorders. First-line cognitive behavioral therapy with or without medication can produce rapid, sustained alleviation of …
Hydrocortisone in Severe Community-Acquired Pneumonia | New …
Mar 21, 2023 · New perspectives on community-acquired pneumonia in 388 406 patients: results from a nationwide mandatory performance measurement programme in healthcare quality. …
The Emerging Threat of H5N1 to Human Health | New England …
Dec 31, 2024 · Against this background, more humans have come into contact with HPAI A(H5N1). Investigators now report in the Journal a series of human cases from the United …
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH …
Feb 7, 2024 · From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne …
CD19 CAR T-Cell Therapy in Autoimmune Disease - The New …
Feb 21, 2024 · Treatment for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term immune …
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Dec 10, 2020 · In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two …
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell …
Sep 13, 2024 · Durvalumab is a selective, high-affinity human IgG1 monoclonal antibody that binds to programmed death ligand 1 (PD-L1), blocking its interaction with programmed death 1 …
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without ...
Jun 14, 2024 · Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. However, data regarding the …
Empagliflozin in Patients with Chronic Kidney Disease | New …
Nov 4, 2022 · We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m 2 of body-surface …